Investing.com - Arbutus Biopharma (NASDAQ: ABUS) reported second quarter EPS of $-0.110, worse than the analyst estimate of $-0.100. Revenue for the quarter came in at $1.73M versus the consensus estimate of $1.77M.
Arbutus Biopharma's stock price closed at $3.77. It is up 39.110% in the last 3 months and up 81.250% in the last 12 months.
Arbutus Biopharma saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Arbutus Biopharma's stock price’s past reactions to earnings here.
According to InvestingPro, Arbutus Biopharma's Financial Health score is "fair performance".
Check out Arbutus Biopharma's recent earnings performance, and Arbutus Biopharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar